Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.
2.

Pharmacokinetic optimisation of treatment with oral etoposide.

Toffoli G, Corona G, Basso B, Boiocchi M.

Clin Pharmacokinet. 2004;43(7):441-66. Review.

PMID:
15139794
3.

Population pharmacokinetics and pharmacodynamics of oral etoposide.

Toffoli G, Corona G, Sorio R, Robieux I, Basso B, Colussi AM, Boiocchi M.

Br J Clin Pharmacol. 2001 Nov;52(5):511-9.

4.

Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer.

Zucchetti M, Pagani O, Torri V, Sessa C, D'Incalci M, De Fusco M, de Jong J, Gentili D, Martinelli G, Tinazzi A, et al.

Clin Cancer Res. 1995 Dec;1(12):1517-24.

5.

Involvement of P-glycoprotein and CYP 3A4 in the enhancement of etoposide bioavailability by a piperine analogue.

Najar IA, Sharma SC, Singh GD, Koul S, Gupta PN, Javed S, Johri RK.

Chem Biol Interact. 2011 Apr 25;190(2-3):84-90. doi: 10.1016/j.cbi.2011.02.011. Epub 2011 Feb 17.

PMID:
21333639
6.

Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children.

Kersting G, Willmann S, Würthwein G, Lippert J, Boos J, Hempel G.

Cancer Chemother Pharmacol. 2012 Feb;69(2):397-405. doi: 10.1007/s00280-011-1706-9. Epub 2011 Jul 26.

PMID:
21789689
7.

Population pharmacokinetics of etoposide: application to therapeutic drug monitoring.

Ciccolini J, Monjanel-Mouterde S, Bun SS, Blanc C, Duffaud F, Favre R, Durand A.

Ther Drug Monit. 2002 Dec;24(6):709-14.

PMID:
12451286
8.

Population pharmacokinetics of total and unbound etoposide.

Nguyen L, Chatelut E, Chevreau C, Tranchand B, Lochon I, Bachaud JM, Pujol A, Houin G, Bugat R, Canal P.

Cancer Chemother Pharmacol. 1998;41(2):125-32.

PMID:
9443625
9.

Bioavailability of etoposide after oral administration of the solution marketed for intravenous use: therapeutic and pharmacoeconomic perspectives.

Aguilar Ponce JL, Flores-Picazo Y, Pérez-Urizar J, Castañeda-Hernández G, Zinser-Sierra JW, Dueñas-González A, Calderón-Flores E, Segura-Pacheco BA, de la Garza-Salazar J.

Arch Med Res. 1999 May-Jun;30(3):212-5.

PMID:
10427872
10.

[Pharmacokinetic aspects of oral administration of etoposide].

Tillmann B, Krümpelmann S, Würthwein G, Wagner A, Schulze-Westhoff P, Hempel G, Jürgens H, Boos J.

Klin Padiatr. 1998 Jul-Aug;210(4):159-64. German.

PMID:
9743946
11.

Plasma pharmacokinetics of etoposide (VP-16) after i.v. administration to children.

Eksborg S, Söderhäll S, Frostvik-Stolt M, Lindberg A, Liliemark E.

Anticancer Drugs. 2000 Apr;11(4):237-41.

PMID:
10898537
12.

Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide.

Rezaï K, Lokiec F, Grandjean I, Weill S, de Cremoux P, Bordier V, Ekue R, Garcia M, Poupon MF, Decaudin D.

BMC Pharmacol. 2007 Oct 27;7:13.

13.

Pharmacological attempts to improve the bioavailability of oral etoposide.

Joel SP, Clark PI, Heap L, Webster L, Robbins S, Craft H, Slevin ML.

Cancer Chemother Pharmacol. 1995;37(1-2):125-33.

PMID:
7497581
14.

Level of evidence for therapeutic drug monitoring for etoposide after oral administration.

Gerritsen-van Schieveen P, Royer B; Therapeutic Drug Monitoring Group of the French Society of Pharmacology and Therapeutics..

Fundam Clin Pharmacol. 2011 Jun;25(3):277-82. doi: 10.1111/j.1472-8206.2010.00856.x. Review.

PMID:
20608987
15.

Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration.

Hande K, Messenger M, Wagner J, Krozely M, Kaul S.

Clin Cancer Res. 1999 Oct;5(10):2742-7.

16.

Fractionated doses of oral etoposide in the treatment of patients with aids-related kaposi sarcoma: a clinical and pharmacologic study to improve therapeutic index.

Sprinz E, Caldas AP, Mans DR, Cancela A, DiLeone L, Dalla Costa T, Schwartsmann G.

Am J Clin Oncol. 2001 Apr;24(2):177-84.

PMID:
11319295
17.

Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas.

Kroschinsky FP, Friedrichsen K, Mueller J, Pursche S, Haenel M, Prondzinsky R, Ehninger G, Schleyer E.

Cancer Chemother Pharmacol. 2008 Apr;61(5):785-90. Epub 2007 Jun 20.

PMID:
17579865
19.

Effect of grapefruit juice intake on etoposide bioavailability.

Reif S, Nicolson MC, Bisset D, Reid M, Kloft C, Jaehde U, McLeod HL.

Eur J Clin Pharmacol. 2002 Oct;58(7):491-4. Epub 2002 Sep 3.

PMID:
12389073
20.

Etoposide encapsulated in positively charged liposomes: pharmacokinetic studies in mice and formulation stability studies.

Sengupta S, Tyagi P, Velpandian T, Gupta YK, Gupta SK.

Pharmacol Res. 2000 Nov;42(5):459-64.

PMID:
11023708

Supplemental Content

Support Center